Save up -80% on Pazopanib
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Votrient
|price without discount in nearest pharmacy. Price may vary.|
We offer free Pazopanib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Pazopanib every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Pazopanib volume of distribution
Vd steady state, IV administration 5 mg, cancer patient = 11.1 L (range of 9.15 – 13.4)
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Pazopanib
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Pazopanib mechanism of action
Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth.
Dosage forms of Pazopanib
GW 78603 GW786034
Novartis Pharmaceuticals Canada Inc
Humans and other mammals
Indication of Pazopanib
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Toxicity of Pazopanib
Severe or fatal hepatotoxicity, manifested as increases in serum concentrations of aminotransferases and bilirubin, has been reported in patients receiving pazopanib. If hepatotoxicity occurs, pazopanib dosage should be reduced, or therapy should be interrupted or permanently discontinued. Woman should avoid the use of pazopanib during pregnancy. While there are no adequate and well-controlled studies in pregnant women, pazopanib has been shown to be teratogenic, embryotoxic, fetotoxic, and abortifacient in animal studies.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Pazopanib on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.